| Biography | |
|---|---|
 Prof. Tao Ren The First Affiliated Hospital, Chengdu Medical College, China |
|
| Title: Proteomics reveals a therapeutic vulnerability via combined blockade of APE1 and autophagy in lung cancer A549 cells | |
| Abstract:
Drug resistance is a major cause of therapeutic failure which is often associated with elevated autophagy and APE1 expression. Herein, we investigated the role of APE1 and autophagy in KRASG12S mutant A549 cells treated with cisplatin. We first revealed that 72 canonical pathways including BER and autophagy signaling responding to cisplatin in A549 cells via quantitative proteomics. Subsequently, we showed that cisplatin markedly caused autophagy and apoptosis in A549 cells, accompany with remarkable APE1 increase. Suppression of autophagy enhanced the inhibition of cisplatin on cell growth, proliferation, and colony formation; furthermore, APE1 inhibition enhanced the expression of LC3-I/II, together which suggest that APE1 and autophagy are compensatory for cell survival responding to cisplatin with the involvement of APE1-p53-LC3 complex assembly. Combined blockade of APE1 and autophagy markedly enhanced cisplatin-induced apoptosis in A549 cells, accompany with p53 activation. Of note, the dual inhibition significantly overcame cisplatin resistance in A549/CDDP cisplatin-acquired resistant cells. In conclusion, dual inhibition of APE1 and autophagy enhances apoptosis in parental and cisplatin resistant A549 cells via regulation of APE1-p53-LC3 complex assembly, which provides a therapeutic vulnerability to overcome NSCLC cisplatin resistance.
| |
| Biography: Main research interest: Cancer pharmacology and anticancer drug chemothreapy and drug-resistance. APE1 and tumor. Education: 2012-2015 Ph.D. in Oncology Scicence in Daping hospital, Third Millitary Medical University. Chongqing , China. 2014-2015 Visiting Scholar, in Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, Florida, USA. 2005-2008 Master Degree. Chongqing Medical University. Chongqing, China 1996-2001 Bachelor. North Sichuan Medical College. Nanchong City, China.
Work experience: 2018 to present Prof. Directory of Oncology Department, first affiliated hospital, Chengdu Medical College. 2016 to 2018 Vice-prof. Directory of Oncology Department, Sichuan Science City Hospital. 2011 to 2016 from resident to vice-prof. Oncology Department, the affiliated hospital, North Sichuan Medical College. Nanchong, China
Selected publications as first author. （1）Ren Tao, Shan J, Li M, Qing Y, Qian C, Wang G, Li Q, Lu G, Li C, Peng Y, Luo H, Zhang S, Yang Y, Cheng Y, Wang D, Zhou SF. Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer. Drug Design, Development and Therapy, 2015,9:2887-2910. (IF=2.935) （2）Ren Tao, Shan J, Qing Y, Qian C, Li Q, Lu G, Li M, Li C, Peng Y, Luo H, Zhang S, Zhang W, Wang D, Zhou SF. Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of APE1-activated IL-6/STAT3 signaling pathway. Drug Design, Development and Therapy, 2014,8:2517-2529. (IF=2.935) （3）Ren Tao, Qing Yi, Dai Nan, Li Mengxia, Qian Chengyuan, Yang Yuxing, Cheng Yi, Li Zheng, Zhang Shiheng, Zhong Zhaoyang, Wang Dong. Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells. Cancer Sci. 2014,105(2):186-194.（IF=4.372） （4）Tao Ren, Dong Wang. Effects of Sox2 on cisplatin-resistant cells A549/DDP stem-like properties in lung adenocarcinoma. Chin J Cancer Prev. Treat.,2018,25(19):1351-1357 （5）Tao Ren, Xian-feng Wang, Yong-quan Tang. siRNA-mediated suppression of SNCG promotes radiosensitivity in breast cancer MDA-MB231 cells. Modern Oncology,2017,25(14):2215-2218 | |
